TLDR:
- Epsilogen, a UK-based company specializing in IgE antibodies for cancer treatment, raised £12.5M in Series B funding.
- The funding will be used to expand operations and R&D.
Epsilogen, a London-based company focused on developing immunoglobulin E (IgE) antibodies to treat cancer, has successfully closed a £12.5M Series B extension financing round. This brings the total amount raised to £43.25M and includes investments from British Patient Capital, Novartis Venture Fund, Epidarex Capital, 3B Future Health Fund, and ALSA Ventures. The company, led by CEO Tim Wilson, plans to use the funds to expand its operations and research and development efforts.
The key focus of Epsilogen is advancing IgE antibodies for cancer treatment, leveraging its natural defense mechanisms against parasites. The company’s lead product candidate, MOv18 IgE, has shown promising results in a Phase I trial, demonstrating safety and early signs of clinical activity. Epsilogen has also achieved large-scale GMP manufacture of MOv18 IgE, a significant milestone for IgE antibodies, and will soon initiate a Phase Ib trial in platinum-resistant ovarian cancer patients.
Founded in 2017 as a spin-out of King’s College London, Epsilogen has secured venture capital financing from various investors, including Epidarex Capital, Novartis Venture Fund, 3B Future Health Fund, British Patient Capital, ALSA Ventures, and Schroders Capital. The company is also working on developing a pipeline of IgE therapies in oncology, as well as proprietary platforms such as IgE bispecifics and unique IgE/IgG combination antibody molecules (IgEGs) with enhanced functionality.
Overall, Epsilogen’s successful Series B financing round marks a significant milestone in its journey to revolutionize cancer treatment through innovative IgE antibody therapies.
